Home  /  Resource Library  /  EHA 2019 | Two-year follow-up of CheckMate 205: nivolumab plus doxorubicin, vinblastine, and dacarbazine in newly diagnosed advanced-stage cHL

EHA 2019 | Two-year follow-up of CheckMate 205: nivolumab plus doxorubicin, vinblastine, and dacarbazine in newly diagnosed advanced-stage cHL

EHA 2019: Results of a phase II study investigating nivolumab in combination with chemotherapy for first line treatment of Hodgkin lymphoma.